Medicure Inc. (OTCMKTS:MCUJF) Stock Short Interest Drops 93.1%

Medicure Inc. (OTCMKTS:MCUJF) saw a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 3,348 shares, a decrease of 93.1% from the September 30th total of 48,345 shares. Based on an average daily trading volume, of 26,042 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are short sold.

Medicure Price Performance

MCUJF traded up $0.16 during trading on Monday, reaching $3.16. 18,534 shares of the company’s stock were exchanged, compared to its average volume of 14,800. Medicure has a 1 year low of $0.67 and a 1 year high of $3.45. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.64 and a current ratio of 0.97. The company’s fifty day simple moving average is $1.97 and its 200-day simple moving average is $1.11.

Medicure (OTCMKTS:MCUJF) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.05). Medicure had a negative net margin of 23.14% and a negative return on equity of 54.55%. The business had revenue of $5.36 million during the quarter, compared to analysts’ expectations of $2.45 million.

Medicure Company Profile

Medicure Inc is a Canadian pharmaceutical company focused on developing and commercializing therapies for cardiovascular and related serious medical conditions. The company is headquartered in Winnipeg, Manitoba, and serves healthcare markets primarily through its U.S. pharmaceutical operations.

Medicure’s principal commercial product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used to help reduce thrombotic cardiovascular events in patients with acute coronary syndromes, including non-ST-segment elevation acute coronary syndrome.